Related Experiment Videos
[Chemoradiation in pancreatic carcinoma]
1Département de radiothérapie-oncologie, centre hospitalier Lyon-Sud, 69495 cedex, Pierre-Bénite, France.
Summary
Pancreatic cancer has a poor prognosis. This review explores chemoradiation strategies, including adjuvant, preoperative, and neoadjuvant approaches for resectable and locally advanced pancreatic cancer, updating trends with 5-fluorouracil and gemcitabine.
Area of Science:
- Oncology
- Gastroenterology
- Surgical Oncology
Context:
- Pancreatic carcinoma presents a significant therapeutic challenge with dismal survival rates.
- Resection is feasible in only a small percentage of patients, and long-term survival post-resection remains limited.
- Current treatment paradigms necessitate exploration of novel therapeutic strategies.
Purpose:
- To provide an updated review of chemoradiation trends in pancreatic cancer management.
- To discuss the role of adjuvant and preoperative chemoradiation in resectable pancreatic adenocarcinoma.
- To examine recent advancements in chemoradiation for locally advanced pancreatic cancer.
Summary:
- The paper reviews adjuvant chemoradiation following pancreatic surgery.
- It evaluates preoperative chemoradiation for localized, resectable pancreatic adenocarcinoma.
- Recent studies on chemoradiation for locally advanced disease, utilizing 5-fluorouracil and gemcitabine, are discussed.
Impact:
- This review synthesizes current evidence on chemoradiation for pancreatic cancer.
- It offers insights into optimizing treatment strategies for both resectable and locally advanced disease.
- The findings aim to inform clinical decision-making and improve patient outcomes in pancreatic cancer care.